Wayne, PA, United States of America

Douglas Abel

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Advanced Aesthetic Technologies, Inc.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Douglas Abel: Innovator in Dermal Fillers

Introduction

Douglas Abel is a notable inventor based in Wayne, Pennsylvania. He has made significant contributions to the field of aesthetic medicine, particularly in the development of dermal fillers. His innovative approach focuses on enhancing the safety and effectiveness of these cosmetic procedures.

Latest Patents

Douglas Abel holds a patent for "Methods, kits and compositions for novel agarose-based dermal filler with enhanced rheological properties." This patent discloses safe and effective methods for performing dermal filling procedures. The agarose-based dermal fillers he developed offer advanced rheological properties, making them easier to inject and disperse compared to traditional hyaluronic acid-based fillers. Additionally, these fillers provide safety advantages, as they can be dispersed quickly to minimize the risk of injury to patients.

Career Highlights

Abel is associated with Advanced Aesthetic Technologies, Inc., where he applies his expertise in developing innovative solutions for the cosmetic industry. His work has been instrumental in advancing the standards of dermal fillers, ensuring that they are not only effective but also safe for patients.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Douglas Abel's contributions to the field of dermal fillers highlight his commitment to innovation and safety in aesthetic medicine. His work continues to influence the industry positively, paving the way for safer and more effective cosmetic procedures.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…